Inhibiting Cancer Metastasis via P-Selectin Binding Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer metastasis is challenging to inhibit due to the complex interactions between cancer cells and the host microenvironment, particularly involving selectin molecules and chondroitin sulfate proteoglycans, which facilitate adhesion and migration of cancer cells.
Innovation Solution
Inhibiting the binding of P-Selectin to chondroitin sulfate proteoglycans on cancer cells by using chondroitin sulfate ligands, P-Selectin ligands, or inhibitors of chondroitin sulfate synthesis/sulfation, thereby blocking interactions with platelets and endothelial cells, which are key steps in metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If P-Selectin binds to chondroitin sulfate proteoglycans on cancer cells, then adhesion and migration of cancer cells is facilitated, but metastasis is promoted
Solution Approach 1:
The patent uses chondroitin sulfate ligands as intermediary molecules that bind to P-Selectin on platelets and endothelial cells, preventing direct interaction between these cells and cancer cells. This mediator blocks the adhesion pathway without affecting the natural functions of P-Selectin or chondroitin sulfate proteoglycans, thereby inhibiting metastasis while preserving normal physiological processes.
Solution Approach 2:
The patent extracts and isolates chondroitin sulfate from cancer cells and uses it as a therapeutic agent. By separating this specific molecule from the complex cancer cell surface, the invention creates a purified inhibitor that can be administered systemically to block P-Selectin binding, thereby preventing metastasis without removing the entire cancer cell or its other functions.
2Adaptability or versatility
If chondroitin sulfate proteoglycans interact with platelets and endothelial cells, then tumor cell interaction at secondary sites is enabled, but metastasis is inhibited when blocked
Solution Approach 1:
The patent employs chondroitin sulfate ligands that can bind to P-Selectin on multiple cell types including platelets and endothelial cells simultaneously. This universal ligand blocks multiple metastatic pathways through a single mechanism, making the therapy effective against various metastatic scenarios without requiring separate inhibitors for each cell type interaction.
Solution Approach 2:
The patent administers chondroitin sulfate ligands before cancer cells reach secondary sites, pre-blocking the P-Selectin binding sites on platelets and endothelial cells. This preliminary action ensures that when cancer cells arrive at distant sites, the adhesion molecules are already occupied or inhibited, preventing metastatic colonization before it can occur.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Preventing tumor cell interaction with platelets and endothelial cells at secondary sites, thereby inhibiting metastasis, as demonstrated by reduced lung metastasis in experimental models.
Implementation Method 1
P-Selectin binds to chondroitin sulfate proteoglycans on the surface of cancer cells
Implementation Method 2
Inhibiting the binding of P-Selectin to chondroitin sulfate proteoglycans on cancer cells by using chondroitin sulfate ligands
Data Source
AI summary
P-Selectin on platelets and endothelium binds cell surface chondroitin sulfate (CS) proteoglycans, which are abundantly and stably expressed on the surface many cancer cells. Binding of the cancer cells through the CS moieties may be blocked to inhibit the interaction of cancer cells with platelets and endothelium. The present inventors disclose compositions and methods for the inhibition of cancer metastasis.